MDxHealth Dividends and Buybacks

Dividend criteria checks 0/6

MDxHealth does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-44.0%

Buyback Yield

Total Shareholder Yield	-44.0%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

Oct 05

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MDXH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDXH's dividend payments have been increasing.

Dividend Yield vs Market

MDxHealth Dividend Yield vs Market

How does MDXH dividend yield compare to the market?
Segment	Dividend Yield
Company (MDXH)	n/a
Market Bottom 25% (BE)	2.8%
Market Top 25% (BE)	7.7%
Industry Average (Biotechs)	1.6%
Analyst forecast (MDXH) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate MDXH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDXH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MDXH's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MDXH has not reported any payouts.

MDxHealth Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

MDxHealth SA Provides Revenue Guidance for the Year 2025

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million.

Mdxhealth SA Raises Earnings Guidance for the Year 2024

MDxHealth SA Revises Earnings Guidance for the Year 2024

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

MDxHealth SA Maintains Earnings Guidance for the Year 2024

MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors

MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024

MDxHealth SA to Report Q1, 2024 Results on May 08, 2024

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

New minor risk - Profitability

MDxHealth SA Provides Earnings Guidance for the Year 2023

MDxHealth SA Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

MDxHealth SA to Report Q3, 2023 Results on Oct 09, 2023

Consensus EPS estimates fall by 10%, revenue upgraded

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

New major risk - Share price stability

MDxHealth SA Reaffirms Revenue Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Full year 2022 earnings released: US$0.28 loss per share (vs US$0.24 loss in FY 2021)

Third quarter 2022 earnings released: US$0.078 loss per share (vs US$0.06 loss in 3Q 2021)

MDxHealth SA to Report First Half, 2023 Results on Aug 23, 2023

MDxHealth SA Provides Revenue Guidance for the Fiscal Year 2023

MDxHealth SA Revises Revenue Guidance for the Fiscal Year 2022

Price target increased to €1.20

MDxHealth SA Reaffirms Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.059 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.072 loss per share (vs US$0.06 loss in 2Q 2021)

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

Mdxhealth Sa Announces Resignation of Rudi Mariën as Non-Executive Director

Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

Full year 2021 earnings released

Price target increased to €1.20

MDxHealth SA Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

First half 2021 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1H 2020)

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.69 loss in FY 2019)

Revenue misses expectations

MDxHealth SA to Report Fiscal Year 2020 Results on Apr 28, 2021

MDxHealth SA to Report Fiscal Year 2020 Results on Mar 03, 2021

MDxHealth SA to Report First Half, 2021 Results on Aug 26, 2021

New 90-day high: €1.07

MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

New 90-day high: €1.00

Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Price target raised to €1.00

MDxHealth SA Suspends 2020 Guidance

New 90-day low - €0.69

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies